Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;13(4):349-55.
doi: 10.1097/GIM.0b013e3182091ba4.

Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk

Douglas E Levy  1 , Stacey D Byfield, Catherine B Comstock, Judy E Garber, Sapna Syngal, William H Crown, Alexandra E Shields
Affiliations

Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk

Douglas E Levy et al. Genet Med. 2011 Apr.

Abstract

Purpose: Women with early-onset (age ≤40 years) breast cancer are at high risk of carrying deleterious mutations in the BRCA1/2 genes; genetic assessment is thus recommended. Knowledge of BRCA1/2 mutation status is useful in guiding treatment decisions. To date, there has been no national study of BRCA1/2 testing among newly diagnosed women.

Methods: We used administrative data (2004-2007) from a national sample of 14.4 million commercially insured patients to identify newly diagnosed, early-onset breast cancer cases among women aged 20-40 years (n = 1474). Cox models assessed BRCA1/2 testing, adjusting for covariates and differential lengths of follow-up.

Results: Overall, 30% of women aged 40 years or younger received BRCA1/2 testing. In adjusted analyses, women of Jewish ethnicity were significantly more likely to be tested (hazard ratio = 2.83, 95% confidence interval: 1.52-5.28), whereas black women (hazard ratio = 0.34, 95% 0.18-0.64) and Hispanic women (hazard ratio = 0.52, 95% confidence interval: 0.33-0.81) were significantly less likely to be tested than non-Jewish white women. Those enrolled in a health maintenance organization (hazard ratio = 0.73, 95% confidence interval: 0.54-0.99) were significantly less likely to receive BRCA1/2 testing than those point of service insurance plans. Testing rates increased sharply for women diagnosed in 2007 compared with 2004.

Conclusions: In this national sample of patients with newly diagnosed breast cancer at high risk for BRCA1/2 mutations, genetic assessment was low, with marked racial differences in testing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative distribution of time from diagnosis to genetic testing for patients receiving testing
See this image and copyright information in PMC

References

    1. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003 Jun 15;21(12):2397–2406. - PubMed
    1. U.S. Preventive Services Taskforce. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005 Sep 6;143(5):355–361. - PubMed
    1. National Comprehensive Cancer Network. [Accessed September 28, 2009];Genetic/Familial High-Risk Asessment: Breast and Ovarian V.1.2009. 2009 http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf.
    1. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996 May;14(5):1730–1736. discussion 1737–1740. - PubMed
    1. Myriad Genetics. [Accessed May 14, 2008];Myriad Genetics Awarded Three U. S. Patents And Eight International Patents. 2001 News release. Available at: http://www.myriad.com/news/release/210288.

Publication types